Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though not statistically significant. Lumakras (sotorasib) plus Vectibix (panitumumab) generated overall survival data and response rates, as well as earlier progression-free survival and safety […]
Lumakras Plus Vectibix Shows Potential in KRAS G12C Colorectal Cancer Read More »
The FDA approved Welireg for those with locally advanced, unresectable or metastatic pheochromocytoma or paraganglioma: © stock.adobe.com. The United States Food and Drug Administration (FS) approved Welireg (belzutifan) for adult and pediatric patients 12 years and older with locally advanced,
FDA Approves Welireg for Pheochromocytoma and Paraganglioma Read More »
Aidixi plus toripalimab met study end points for patients with HER2-expressing urothelial carcinoma: © stock.adobe.com. Aidixi (disitamab vedotin) in combination with the PD-L1 inhibitor toripalimab reached its two primary end points of progression-free survival and overall survival compared with the
Aidixi Combination Therapy Improves Survival in Urothelial Carcinoma Read More »
The addition of Erleada to ADT may provide less benefit in patients with metastatic castration-sensitive prostate cancer and fewer bone metastases: © stock.adobe.com. The addition of Erleada (apalutamide) to androgen-deprivation therapy (ADT) may provide less benefit in patients with metastatic castration-sensitive
Bone Metastasis Count May Guide Erleada Treatment in Prostate Cancer Read More »
A Perjeta combo led to a significant overall survival benefit in HER2+ early-stage breast cancer: © stock.adobe.com. Treatment with Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy (Perjeta-based regimen) for one year as post-surgery treatment showed a statistically significant overall survival (OS)
Perjeta Regimen Improves Survival in HER2+ Early-Stage Breast Cancer Read More »
An Enhertu regimen significantly improved pathologic complete responses for high-risk HER2+ early-stage breast cancer: © karrastock – stock.adobe.com Enhertu (fam-trastuzumab deruxtecan-nxki) followed by Taxol (paclitaxel), Herceptin (trastuzumab) and Perjeta (pertuzumab), also known as THP, showed a statistically significant and clinically
Enhertu Regimen Improves Responses in High-Risk HER2+ Breast Cancer Read More »
Danyelza is now a recommended treatment in NCCN guidelines for high-risk neuroblastoma: © sudok1 – stock.adobe.com. Danyelza is now recommended by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as an NCCN category 2a treatment option for
Danyelza Added to NCCN Guidelines for High-Risk Neuroblastoma Read More »
Avmapki Fakzynja receives accelerated FDA approval for previously treated low-grade serous ovarian cancer with KRAS mutations: © stock.adobe.com. The United States Food and Drug Administration has granted accelerated approval to the Avmapki Fakzynja Co-pack (a combination of avutometinib and defactinib)
FDA Approves Avmapki Fakzynja Co-pack for KRAS Serous Ovarian Cancer Read More »
Biomarker testing is vital for all patients with lung cancer: © stock.adobe.com. Biomarker testing for patients with lung cancer is critical, especially for those with young onset lung cancer, according to study findings presented at an Educated Patient® Lung Cancer
Biomarker Testing Remains Crucial for Young Patients With Lung Cancer Read More »
Imfinzi plus BCG induction and maintenance statistically and clinically meaningfully improved DFS in some with bladder cancer: © stock.adobe.com. One year of treatment with Imfinzi (durvalumab) plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy showed a statistically and clinically meaningful
Imfinzi Regimen Improves Disease-Free Survival in Early Bladder Cancer Read More »
